Who are Low dose carbamazepine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): 0.33% ropivacaine 250ml, bucain + fentanyl, Anesthesia (Lidocaine 15%), Lidocaine aerosol 2.4% topical, Buffered Lidocaine, Synera patch for 12hrs/day.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-carbamazepine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Low dose carbamazepine — Competitive Intelligence Brief

Low dose carbamazepine (Low dose carbamazepine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Antiepileptic drug. Area: Neurology.

marketed Anticonvulsant / Antiepileptic drug Voltage-gated sodium channels Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Low dose carbamazepine (Low dose carbamazepine) — Mario Negri Institute for Pharmacological Research. Low-dose carbamazepine reduces sodium channel activity and stabilizes neuronal membranes to prevent abnormal electrical activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Low dose carbamazepine TARGET	Low dose carbamazepine	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels
0.33% ropivacaine 250ml	0.33% ropivacaine 250ml	Guangzhou General Hospital of Guangzhou Military Command	marketed	Local anesthetic	Voltage-gated sodium channels
bucain + fentanyl	bucain + fentanyl	University of Debrecen	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (bucain); mu-opioid receptor (fentanyl)
Anesthesia (Lidocaine 15%)	Anesthesia (Lidocaine 15%)	Lumbini Medical College	marketed	Local anesthetic	Voltage-gated sodium channels
Lidocaine aerosol 2.4% topical	Lidocaine aerosol 2.4% topical	Jiangang Song	marketed	Local anesthetic	Voltage-gated sodium channels
Buffered Lidocaine	Buffered Lidocaine	University of California, San Diego	marketed	Local anesthetic	Voltage-gated sodium channels
Synera patch for 12hrs/day	Synera patch for 12hrs/day	International Clinical Research Institute	marketed	Topical local anesthetic combination	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Antiepileptic drug class)

Mario Negri Institute for Pharmacological Research · 3 drugs in this class
Eisai Inc. · 2 drugs in this class
Affiliated Hospital of Nantong University · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
MaineHealth · 1 drug in this class
UCB Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low dose carbamazepine — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-carbamazepine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab